After years of providing mobile IV therapy across Oklahoma, I've learned that transparency about costs and scheduling makes all the difference in your experience
van Goor
Phase 3 completion is expected in early 2026, with an FDA submission likely in late 2026 and potential approval in 2027
Moreover, in patients with ED, particularly in middle-aged and elderly patients, dynamic PDU may also provide a predictive response for the potential effectiveness of the vasodilative drugs used for ED, as demonstrated by the negative correlation between the severity of penile vascular damage and the clinical response to treatment with PDE5i [38]
Impact: Contributes to 8 of the 10 leading causes of death in the U.S (risk factor for many diseases, including atherosclerotic vascular disease (causing heart attacks and strokes), type 2 diabetes, arthritis, several types of cancer, and premature death)